Novellia Raises $18 Million to Expand RWD Platform

Rare Daily Staff

Novellia said it raised $18 million in a series A financing round to expand its patient-consented real-world data platform and address longstanding inefficiencies in how pharmaceutical companies access clinical insights.

Spark Capital led the funding round, which included participation from Khosla Ventures, Acrew Capital, Bling Capital and TMV. The round brings Novellia’s total funding to $28 million.

Novellia is positioning itself as a new model in the $50 billion real-world data market, which has traditionally relied on aggregated insurance claims and hospital records. Those datasets are often fragmented, delayed, and disconnected from the patient experience, limiting their utility in understanding how therapies perform outside controlled clinical trials.

“Behind every patient is a fragmented, incomplete record of their life,” said Shashi Shankar, co-founder and CEO of Novellia. “I watched this up close: first through my grandfather’s cancer journey, and then professionally in pharma, where we were developing therapies without ever seeing the full picture. The system failed patients and researchers at the same time. Novellia changes the course for this whole industry by putting the patient at the center.”

At the core of Novellia’s platform is an AI-driven system that aggregates up to 20 years of patient health records from disparate providers within seconds. The company also announced the launch of a patient-facing mobile app, designed to give individuals centralized access to their medical histories while allowing them to opt in to research use.

Novellia relies on patient-consented data, which it de-identifies and provides to pharmaceutical and diagnostics companies. Its proprietary natural language processing models extract insights from unstructured clinical documents, such as physician notes and lab reports.

Novellia said its platform has already been adopted by several top 10 pharmaceutical companies, as well as emerging diagnostics firms. The company plans to use the new funding to scale its AI capabilities, expand its patient network and deepen partnerships across the life sciences sector.

“Pharma has been working with data that is too slow and too disconnected from patients,” said Alex Finkelstein, general partner at Spark Capital. “Novellia is building infrastructure that directly links patient experience with research, which could materially change how medicines are developed.”